- Home
- WTW vs BIIB Comparison
WTW vs BIIB Comparison
Compare WTW & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WTW
- BIIB
- Stock Information
- Founded
- WTW 1828
- BIIB 1978
- Country
- WTW United Kingdom
- BIIB United States
- Employees
- WTW N/A
- BIIB N/A
- Industry
- WTW Specialty Insurers
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- WTW Finance
- BIIB Health Care
- Exchange
- WTW Nasdaq
- BIIB Nasdaq
- Market Cap
- WTW 31.3B
- BIIB 25.1B
- IPO Year
- WTW N/A
- BIIB 1991
- Fundamental
- Price
- WTW $317.57
- BIIB $146.47
- Analyst Decision
- WTW Buy
- BIIB Buy
- Analyst Count
- WTW 15
- BIIB 26
- Target Price
- WTW $323.47
- BIIB $248.00
- AVG Volume (30 Days)
- WTW 896.6K
- BIIB 1.7M
- Earning Date
- WTW 02-04-2025
- BIIB 02-11-2025
- Dividend Yield
- WTW 1.11%
- BIIB N/A
- EPS Growth
- WTW N/A
- BIIB 10.05
- EPS
- WTW N/A
- BIIB 11.06
- Revenue
- WTW $9,809,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- WTW $5.67
- BIIB N/A
- Revenue Next Year
- WTW $0.36
- BIIB N/A
- P/E Ratio
- WTW N/A
- BIIB $13.24
- Revenue Growth
- WTW 5.58
- BIIB N/A
- 52 Week Low
- WTW $237.08
- BIIB $145.07
- 52 Week High
- WTW $334.99
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- WTW 55.14
- BIIB 24.17
- Support Level
- WTW $306.51
- BIIB $148.60
- Resistance Level
- WTW $315.40
- BIIB $154.24
- Average True Range (ATR)
- WTW 6.18
- BIIB 3.71
- MACD
- WTW -1.13
- BIIB -0.37
- Stochastic Oscillator
- WTW 39.95
- BIIB 7.48
About WTW Willis Towers Watson Public Limited Company
In January 2016, Towers Watson and Willis Group merged to form Willis Towers Watson, a global advisory, insurance brokerage, and solutions company. The company operates in two business segments: health, wealth, and career (its consulting operations) and risk and brokering (its brokerage operations). It has about 48,000 employees.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.